An overview on mRNA-based vaccines to prevent monkeypox infection

• Published in: Journal of nanobiotechnology Vol. 22; no. 1; p. 86
• Main Authors: Natami, Mohammad, Gorgzadeh, Amirsasan, Gholipour, Arsalan, Fatemi, Seyedeh Narges, Firouzeh, Nima, Zokaei, Maryam, Mohammed Ali, Saad Hasan, Kheradjoo, Hadis, Sedighi, Somayeh, Gholizadeh, Omid, Kalavi, Shaylan
• Format: Journal Article
• Language: English
• Published: England BioMed Central 01.03.2024
• Subjects: Antigens; Clinical trials; Collaboration; Cross-protection; Data analysis; Disease; Epidemics; Fatalities; Immune response; Immune system; Immunology; Infections; Monkeypox; mRNA; mRNA vaccines; Pandemics; Prairie dogs; Public health; Regulatory agencies; Ribonucleic acid; Risk assessment; RNA; Severe acute respiratory syndrome coronavirus 2; Smallpox; Vaccines; Vaccinia; Viral diseases; Viral infections; Viruses; Womens health; United Kingdom > UK; United States > US; Sudan; Africa; Vaccine; Immunity; Monkeypox infection; mRNA vaccine
• ISSN: 1477-3155; 1477-3155
• DOI: 10.1186/s12951-024-02355-1

The human monkeypox virus (Mpox) is classified as a member of the Poxviridae family and belongs to the Orthopoxvirus genus. Mpox possesses double-stranded DNA, and there are two known genetic clades: those originating in West Africa and the Congo Basin, commonly known as Central African clades. Mpox may be treated with either the vaccinia vaccination or the therapeutics. Modifying the smallpox vaccine for treating and preventing Mpox has shown to be beneficial because of the strong link between smallpox and Mpox viruses and their categorization in the same family. Cross-protection against Mpox is effective with two Food and Drug Administration (FDA)-approved smallpox vaccines (ACAM2000 and JYNNEOSTM). However, ACAM2000 has the potential for significant adverse effects, such as cardiac issues, whereas JYNNEOS has a lower risk profile. Moreover, Mpox has managed to resurface, although with modified characteristics, due to the discontinuation and cessation of the smallpox vaccine for 40 years. The safety and efficacy of the two leading mRNA vaccines against SARS-CoV-2 and its many variants have been shown in clinical trials and subsequent data analysis. This first mRNA treatment model involves injecting patients with messenger RNA to produce target proteins and elicit an immunological response. High potency, the possibility of safe administration, low-cost manufacture, and quick development is just a few of the benefits of RNA-based vaccines that pave the way for a viable alternative to conventional vaccines. When protecting against Mpox infection, mRNA vaccines are pretty efficient and may one day replace the present whole-virus vaccines. Therefore, the purpose of this article is to provide a synopsis of the ongoing research, development, and testing of an mRNA vaccine against Mpox.